Contrasting Establishment Labs (NASDAQ:ESTA) and Todos Med (OTCMKTS:TOMDF)

Todos Med (OTCMKTS:TOMDF) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Valuation & Earnings

This table compares Todos Med and Establishment Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Med	N/A	N/A	N/A	N/A	N/A
Establishment Labs	$166.02 million	11.55	-$84.60 million	($2.84)	-23.23

Todos Med has higher earnings, but lower revenue than Establishment Labs.

Profitability

This table compares Todos Med and Establishment Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Med	N/A	N/A	N/A
Establishment Labs	-43.45%	-235.45%	-22.83%

Institutional & Insider Ownership

72.9% of Establishment Labs shares are held by institutional investors. 11.1% of Establishment Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Todos Med and Establishment Labs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Med	0	0	0	0	0.00
Establishment Labs	1	1	6	0	2.63

Establishment Labs has a consensus price target of $78.86, suggesting a potential upside of 19.55%. Given Establishment Labs’ stronger consensus rating and higher probable upside, analysts clearly believe Establishment Labs is more favorable than Todos Med.

Summary

Establishment Labs beats Todos Med on 6 of the 9 factors compared between the two stocks.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About Establishment Labs

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.